The Centers for Disease Control and Prevention recently updated its 1991 recommendations for the management of hepatitis B virus (HBV)-infected healthcare providers and students to prevent HBV transmission to patients.
The Centers for Disease Control and Prevention (CDC) recently updated its 1991 recommendations for the management of hepatitis B virus (HBV)-infected healthcare providers and students to prevent HBV transmission to patients.
“The primary goal of this report is to promote patient safety while providing risk management and practice guidance to HBV-infected healthcare providers and students, particularly those performing exposure-prone procedures such as certain types of surgery,” wrote Scott D. Holmberg, MD, of the Division of Viral Hepatitis, and colleagues.
They added that HBV infection alone should not disqualify infected healthcare practitioners from practice or study in their medical field and the updated guidelines offer recommendations on prevention strategies, ethical considerations, and recommendations for the chronically infected. The guidelines include the following updates:
The CDC reviewed the literature since the 1991 recommendations were published, finding no additional studies beyond what they were already aware of, the organization reviewed all hepatitis B outbreak investigations conducted by CDC and state officials since 1991 to gather data on HBV transmission. They focused on reports of acute HBV infection related to recent healthcare services as well as reports of HBV-infected providers being dismissed from their roles.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More